三阴性乳腺癌各亚型精准医疗策略研究进展

doi:10.11904/j.issn.1002-3070.2021.06.008

Abstract

Abstract: Triple negative breast cancer(TNBC)accounts for about 15% of the total number of breast cancer.There is no clear target for targeted therapy and endocrine therapy.The treatment method is relatively single,and the recurrence is early.The overall survival rate is poor.The main treatment methods of early TNBC are neoadjuvant chemotherapy and definitive surgery.The proposal of TNBC molecular typing makes the individualized treatment of TNBC enter the era of precision treatment.Precision medicine strategy based on the characteristics of TNBC subtypes can make patients get clinical benefits.This paper aims to review the research progress and clinical benefits of precision medicine strategy of TNBC subtypes.

Key words: Triple negative breast cancer, Immunology, Precision medicine

CLC Number:

R737.9

SHI Runze, LI Zhigao. Research progress of precision medical strategy for different subtypes of triple negative breast cancer[J]. Journal of Practical Oncology, 2021, 35(6): 529-533.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2021.06.008

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2021/V35/I6/529

References

1 Antonio M,Giulia V,Giuseppe C.Recent advances in triple negative breast cancer:the immunotherapy era[J].BMC Med,2019,17(1):90-102.
2 González MS,Pérez MB,Carretero BI,et al.Molecular features of metaplastic breast carcinoma:an infrequent subtype of triple negative breast carcinoma[J].Cancers Basel,2020,12(7):1832-1841.
3 Jiang YZ,Ma D,Suo C,et al.Genomic and transcriptomic landscape of triple negative breast cancer:subtypes and treatment strategies[J].Cancer Cell,2019,35(3):428-440.
4 Zhao S,Ma D,Xiao Y,et al.Molecular subtyping of triple negative breast cancers by Immunohistochemistry:molecular basis and clinical relevance[J].Oncologist,2020,25(10):1481-1491.
5 Jin SL,Susan EY,Yuan Y.Neoadjuvant treatment for triple negative breast cancers:recent progresses and challenges[J].Cancers Basel,2020,12(6):1404-1414.
6 Chen L,Yang L,Yao L,et al.Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients[J].Nat Commun,2018,9(1):1357-1365.
7 O′Leary B,Finn RS,Turner NC.Treating cancer with selective CDK4/6 inhibitors[J].Nat Rev Clin Oncol,2016,13(7):417-430.
8 Astvatsaturyan K,Yue Y,Walts AE,et al.Androgen receptor positive triple negative breast cancer:clinicopathologic,prognostic and predictive features[J].PLoS One,2018,13(6):e0197827.
9 Traina TA,Miller K,Yardley DA,et al.Enzalutamide for the treatment of androgen receptor expressing triple negative breast cancers[J].Clin Oncol,2018,36(9):884-890.
10 Fu LL,Tian M,Li X,et al.Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery[J].Oncotarget,2015,6(8):5501-5516.
11 Park IH,Yang HN,Jeon SY,et al.Anti-tumor activity of BET inhibitors in androgen-receptor-expressing triple negative breast cancer[J].Sci Rep,2019,9(1):13305-13318.
12 Gul A,Leyland JB,Dey N.A combination of the PI3K pathway inhibitor plus cell cycle pathway inhibitor to combat endocrine resistance in hormone receptor positive breast cancer:a genomic algorithm-based treatment approach[J].Am J Cancer Res,2018,8(12):2359-2376.
13 Fassl A,Brain C,Abu RM,et al.Single cell dynamics determines response to CDK4/6 Inhibition in triple negative breast cancers[J].Clin Cancer Res,2017,23(18):5561-5572.
14 Telli ML,Timms KM,Reid J,et al.Homologous recombination deficiency(HRD)Score predicts response to platinum containing neoadjuvant chemotherapy in patients with triple negative breast cancers[J].Clin Cancer Res,2016,22(15):3764-3773.
15 Von MG,Schneeweiss A,Loibl S,et al.Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer(GeparSixto;GBG 66):a randomised phase 2 trial[J].Lancet Oncol,2014,15(7):747-756.
16 Xia LY,Hu QL,Zhang J,et al.Survival outcomes of neoadjuvant versus adjuvant chemotherapy in triple-negative breast cancer:a meta-analysis of 36480 cases[J].World J Surg Oncol,2020,18(1):129-140.
17 Sikov WM,Berry DA,Perou CM,et al.Impact of the addition of carboplatin and/or bevacizu- mab to neoadjuvant once per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer:CALGB 40603(Alliance)[J].J Clin Oncol,2015,33(1):13-21.
18 Gluz O,Nitz U,Liedtke C,et al.Comparison of neoadjuvant nab+paclitaxel+carboplatin vs nab+paclitaxel+gemcitabine in triple-negative breast cancer:randomized WSG-ADAPT-TN trial results[J].J Natl Cancer Inst,2018,110(6):628-637.
19 Toss A,Molinaro E,Venturelli M,et al.BRCA detection rate in an Italian cohort of luminal early-onset and triple negative breast cancer patients without family history:when biology overcomes genealogy[J].Cancers Basel,2020,12(5):1497-1508.
20 Wang N,Li K,Huang WF,et al.BRCA efficacy of platinum in advanced triple negative breast cancer with germline mutation determined by next generation sequencing[J].Chin J Cancer Res,2020,32(2):149-162.
21 Tutt A,Tovey H,Cheang MCU,et al.Carboplatin in BRCA1/2-mutated and triple negative breast cancers BRCAness subgroups:the TNT trial[J].Nat Med,2018,24(5):628-637.
22 Chen X,Wang J,Fu Z et al.Curcumin activates DNA repair pathway in bone marrow to improve carboplatin-induced myelosuppression[J].Sci Rep,2017,7(1):17724-17741.
23 Chopra N,Tovey H,Pearson A,et al.Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancers[J].Nat Commun,2020,11(1):2662-2681.
24 Robson M,Im SA,Senkus E,et al.Olaparib for metastatic breast cancer in patients with a germline BRCA mutation[J].N Engl J Med,2017,377(17):523-533.
25 Ettl J,Quek RGW,Lee KH,et al.Quality of life with talazoparib versus physician′s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation:patient-reported outcomes from the EMBRACA phase III trial[J].Ann Oncol,2018,29(9):1939-1947.
26 Schmid P,Adams S,Rugo HS,et al.Atezolizumab and nab-paclitaxel in advanced triple negative breast cancer[J].N Engl J Med,2018,379(22):2108-2121.
27 Nanda R,Liu MC,Yau C,et al.Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer:an analysis of the ongoing Phase 2 adaptively randomized I-SPY2 trial[J].JAMA Oncol,2020,6(5):1-9.
28 Loibl S,Untch M,Burchardi N,et al.A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple negative breast cancer:clinical results and biomarker analysis of GeparNuevo study[J].Ann Oncol,2019,30(8):1279-1288.
29 Balko JM,Schwarz LJ,Luo N,et al.Triple negative breast cancer with amplification of JAK2 at the 9p24 locus demonstrate JAK2 specific dependence[J].Sci Transl Med,2016,8(334):334-353.
30 Pascual J,Turner NC.Targeting the PI3-kinase pathway in triple negative breast cancers[J].Ann Oncol,2019,30(7):1051-1060.
31 Kim SB,Dent R,Im SA,et al.Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer(LOTUS):a multicentre,randomised,double-blind,placebo-controlled,phase 2 trial[J].Lancet Oncol,2017,18(10):1360-1372.
32 Schmid P,Abraham J,Chan S,et al.Capivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple negative breast cancer:the PAKT trial[J].J Clin Oncol,2020,38(5):423-433.
33 Gerber B,Loibl S,Eidtmann H,et al.Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple negative breast cancer;results from the geparquinto study(GBG 44)[J].Ann Oncol,2013,24(12):2978-2984.

[1]	TONG Xiao, XING Jiani, WANG Lihong. Long-chain noncoding RNA HCP5 promotes triple-negative breast cancer by regulating apoptotic pathway [J]. Journal of Practical Oncology, 2020, 34(4): 321-327.
[2]	JI Qiao, CHEN Li, HE Yuanqiao. Application of drug sensitivity from three-dimensional tissue in individualized precision medical treatment for tumor [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(3): 280-284.
[3]	YU Changyan, ZHEN Lina, LI Hongbing, ZHANG Yue, ZHANG Qingyuan. The correlations between expression of tumor associated macrophages and the prognostic significances in triple negative breast cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(1): 1-6.
[4]	LUO Hongyu, LI Jiaqi, LUAN Jinwei, ZHANG Siliang, LI Xianglan. The progress of radiotherapy in triple negative breast cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(2): 180-183.
[5]	ZHANG Xinyu,WANG Le,ZHANG Qingyuan. Progress on triple negative breast cancer risk factors [J]. PRACTICAL ONCOLOGY JOURNAL, 2014, 28(5): 477-480.
[6]	CAO Hua,YAN Maosheng,ZHENG Tao,XU Ruilian,CHEN Yixin,WANG Shubin,LIU Yajie. Clinical characteristics and prognosis of triple negative breast cancer in 132 cases [J]. PRACTICAL ONCOLOGY JOURNAL, 2009, 23(2): 101-105.

Research progress of precision medical strategy for different subtypes of triple negative breast cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 6

Recommended Articles

Metrics

Comments